Prevalence of @entity73 , @entity308 , and XXXX symptoms among older adults with @entity726 .

@entity1018 @entity1 @entity308 @entity303 @entity73 @entity532 @entity726 @entity51 @entity148 @entity195 @entity2414
PURPOSE: Two factors which may disrupt the ability to adhere to the treatment for @entity726 are @entity73 and @entity532 . Poor adherence to treatment may lead to preventable @entity1018 . Past research in this area has been limited by little focus on older @entity1 with @entity726 , and the use of brief measures of cognition that may not detect @entity51 related to @entity195 . @entity1 AND METHODS: This study examined the prevalence of @entity73 , @entity308 , and @entity148 in a sample of 41 @entity726 @entity1 at a tertiary care @entity726 clinic. They had a mean age of 70.0 years (SD=9.2 y; range: 51 to 86 y) and 70% (n=30) were female. Two cognitive measures commonly used in detecting @entity303 were used to measure cognitive functioning. RESULTS: Controlling for age, @entity2414 was found in approximately 20% of the sample, and impaired executive functioning was found in approximately 22% of the sample. Forty-four percent of the sample scored in the impaired range on one or more measures. Mild-to-moderate @entity308 were found in 12.2% of @entity1 , and 1 @entity1 reported clinically significant @entity148 . CONCLUSIONS: The results from this study indicate that @entity73 may be common in older @entity1 with @entity726 . This has implications for treatment adherence, as difficulties in remembering information may significantly impede the ability to follow instructions from a physician. It is imperative that physicians and caregivers are aware of the prevalence of such conditions, as they are among the first to interact with such individuals. Given the high prevalence of @entity73 and @entity308 , future research should examine the impact of such factors on @entity726 treatment adherence.
